Guardant Health, Inc.

Guardant Health, Inc.

132.80
EUR
+1.08
(+0.82%)
-3.25EPS
21.25BMarket Cap
Feb 25Next Earn
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.36
0.7
2.98
2.37
2.94
3.69
4.4
5.04
6.02
7.83
9.7
Basic EPS, GAAP
-0.65
-1.26
-2.8
-0.84
-2.6
-4
-6.41
-4.28
-3.56
-3.32
-3.68
Free Cash Flow per Basic Share
-0.54
-1.15
-3.04
-0.76
-1.62
-2.8
-3.79
-3.08
-2.24
-1.86
-1.76
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-1.2
-2.29
5.63
8.47
12.96
6.34
0.59
1.3
-1.13
-0.76
-2.05
Tangible Book Value per Share
-1.2
-2.39
5.54
8.27
12.76
6.17
0.44
1.2
-1.21
-1.55
-2.81
Basic Weighted Avg Shares
71
71
30
91
98
101
102
112
123
125
132
Sales/Revenue/Turnover
25
50
91
214
287
374
450
564
739
982
1,279
Operating Margin (%)
-173.66
-153.71
-102.54
-38.42
-88.92
-110
-121.1
-100.14
-60.02
-44.53
-39.41
Depreciation Expense
4
5
7
11
16
22
36
43
42
40
39
Net Income, GAAP
-46
-83
-85
-76
-254
-406
-655
-479
-436
-416
-485
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-182.74
-166.97
-93.85
-35.29
-88.51
-108.57
-145.61
-85.02
-59.05
-42.39
-37.93
Working Capital
89
223
422
525
1,822
919
998
1,141
830
1,163
970
LT Debt
17
- -
- -
33
848
1,361
1,347
1,326
1,307
1,682
1,663
Total Equity
80
309
525
848
1,356
645
60
159
-140
-99
-276
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
-11.81
-24.21
-41.75
-185.65
-438.13
- -
- -
- -

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
28
28
29
LT Borrowings
1,503
1,503
1,502
LT Finance Leases
173
166
160
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
132
134
135
Market Capitalization
12,150
20,030
24,083

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,368
1,365
1,343
Cash, Cash Equivalents & STI
1,103
1,053
1,027
Accounts Receivable, Net
131
140
180
Inventories
84
105
93
Total Current Liabilities
292
339
373
Payables & Accruals
125
145
179
ST Debt
28
28
29
Deferred Revenue
48
45
38

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-39.26%
-28.89%
Free Cash Flow
- -
13.93%
-15.23%
Net Income, GAAP
- -
16.17%
-4.61%
Sales/Revenue/Turnover
- -
28%
32.88%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
168
177
191
202
739
2025
203
232
265
281
982
2026
302
335
361
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.94
-0.84
-0.88
-0.9
-3.56
2025
-0.77
-0.8
-0.74
-1
-3.32
2026
-0.85
-0.9
-0.93
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Helmy Eltoukhy
Full Time Employees
2,506
Sector
Health technology
Industry
Medical specialties
Address
3100 Hanover Street Palo Alto CA United States 94304
IPO Date
Oct 9, 2018
Business
Guardant Health, Inc. is a precision oncology company specializing in blood and tissue-based diagnostic tests, real-world data sets, and AI-driven analytics to enhance cancer detection, treatment, and patient care. Founded in 2012 and headquartered in Palo Alto, California, the company provides a comprehensive portfolio of products including Guardant360 Liquid Biopsy tests (Guardant360, Guardant360 CDx, Guardant360 TissueNext, Guardant360 Response), Guardant Infinity, Guardant Reveal for early-stage cancer, the Shield test for colorectal cancer screening, and GuardantOMNI for biopharmaceutical research. It also offers integrated software solutions like Guardant Connect and research platforms such as Guardant INFORM and Guardant Galaxy. Guardant serves oncology patients, clinicians, and biopharmaceutical companies across the United States and internationally, including direct operations in Asia, the Middle East, and Africa following its full acquisition of Guardant Health AMEA which expanded its reach to 41 countries in those regions. Recent major developments include a strategic multi-year collaboration with Pfizer to leverage Guardant's liquid biopsy technology in global clinical trials and therapeutic development, including access to the Chinese market. The company has advanced its Smart Liquid Biopsy platform with expanded Medicare coverage, notably for its Guardant Reveal and Shield tests, facilitating broader adoption for cancer surveillance and screening. Guardant also completed the full acquisition of Guardant Health AMEA from SoftBank, consolidating its global operations to accelerate market penetration in high cancer burden regions. In 2024, Guardant reported record revenue growth driven by increased reimbursement and volume for Guardant360 assays, and it continues to innovate with new offerings for early detection and therapy response monitoring in multiple cancer indications. This positions Guardant Health as a leading biotechnology firm in precision oncology diagnostics and data analytics worldwide.

Company News

  • Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • Guardant Health Prices $500 Million Convertible Senior Notes Offering

  • Guardant Health Announces Proposed $500.0 Million Offering of Convertible Senior Notes Due 2032

  • Guardant Health Introduces New Epigenomic Applications Providing Deeper Insights for Treatment Selection with Guardant360® Liquid

  • PRECISION Study Published in ESMO Open Highlights Utility of Guardant360® Liquid and Guardant Reveal® to Assess Recurrence Risk After Surgery for Colorectal Cancer Metastases

  • Guardant Health to Participate in Upcoming Investor Conferences

  • What Guardant Health (GH) Said on Its Q3 Earnings Call

  • Guardant Health (GH) Reports Q3 Loss, Tops Revenue Estimates

  • Guardant Health (GH) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

  • Guardant Health Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue Guidance

  • Countdown to Guardant Health (GH) Q3 Earnings: Wall Street Forecasts for Key Metrics

  • Kevin Sayer Joins Guardant Health Board of Directors

  • Guardant Health Wins 2026 Prix Galien USA Award for Best Medical Technology for Shield Blood Test

  • Guardant Health (GH) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

  • Guardant Health Applauds New Law Ensuring Access to Colorectal Cancer Screening Innovations with No Cost-Sharing for Pennsylvanians

  • Allspring Emerging Growth Fund: Q3 2026 Top Contributors And Detractors

  • This Guardant Health Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

  • Here Are Friday’s Top Wall Street Analyst Research Calls: Deckers Outdoor, Globe Life, Guardant Health, Hess Midstream LP, Kimberly-Clark, Natera, NVR, SpaceX, Thermo Fisher Scientific, and More

  • Guardant Health, Inc. (NASDAQ:GH) Stock Has Average Price Target of $190.00

  • Guardant Health Highlights Broad Liquid Biopsy Research Portfolio at ESMO Congress 2026